Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context
Background: Nanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by enhancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in lymph nodes or formed de novo in peripheral tissues during inflammatory responses....
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-12-01
|
| Series: | EBioMedicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396418305346 |
| _version_ | 1818032136568963072 |
|---|---|
| author | Baharak Bahmani Mayuko Uehara Farideh Ordikhani Xiaofei Li Liwei Jiang Naima Banouni Takaharu Ichimura Vivek Kasinath Siawosh K. Eskandari Nasim Annabi Jonathan S. Bromberg Leonard D. Shultz Dale L. Greiner Reza Abdi |
| author_facet | Baharak Bahmani Mayuko Uehara Farideh Ordikhani Xiaofei Li Liwei Jiang Naima Banouni Takaharu Ichimura Vivek Kasinath Siawosh K. Eskandari Nasim Annabi Jonathan S. Bromberg Leonard D. Shultz Dale L. Greiner Reza Abdi |
| author_sort | Baharak Bahmani |
| collection | DOAJ |
| description | Background: Nanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by enhancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in lymph nodes or formed de novo in peripheral tissues during inflammatory responses. They express peripheral node addressin (PNAd), which is recognized by the monoclonal antibody MECA79. Methods: Here, we demonstrated that HEVs form de novo in human pancreatic ductal adenocarcinoma (PDAC). We engineered MECA79 coated nanoparticles (MECA79-NPs) that recognize these ectopic HEVs in PDAC. Findings: The trafficking of MECA79-NPs following intravenous delivery to human PDAC implanted in a humanized mouse model was more robust than non-conjugated NPs. Treatment with MECA79-Taxol-NPs augmented the delivery of Paclitaxel (Taxol) to the tumor site and significantly reduced the tumor size. This effect was associated with a higher apoptosis rate of PDAC cells and reduced vascularization within the tumor. Interpretation: Targeting the HEVs of PDAC using MECA79-NPs could lay the ground for the localized delivery of a wide variety of drugs including chemotherapeutic agents. Fund: National Institutes of Health (NIH) grants: T32-EB016652 (B·B.), NIH Cancer Core Grant CA034196 (L.D.S.), National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (R.A.). Keywords: Pancreatic ductal adenocarcinoma, High endothelial venules, Peripheral node addressin, MECA79 coated nanoparticles, Taxol |
| first_indexed | 2024-12-10T06:02:35Z |
| format | Article |
| id | doaj.art-104b24ab56314f3db459edc5c96d0b6d |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-10T06:02:35Z |
| publishDate | 2018-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-104b24ab56314f3db459edc5c96d0b6d2022-12-22T01:59:47ZengElsevierEBioMedicine2352-39642018-12-01387988Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in contextBaharak Bahmani0Mayuko Uehara1Farideh Ordikhani2Xiaofei Li3Liwei Jiang4Naima Banouni5Takaharu Ichimura6Vivek Kasinath7Siawosh K. Eskandari8Nasim Annabi9Jonathan S. Bromberg10Leonard D. Shultz11Dale L. Greiner12Reza Abdi13Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USARenal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, CA 90095, USADepartment of Surgery and Microbiology and Immunobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USADepartment of Immunology, The Jackson Laboratory, Bar Harbor, ME 04609, USADepartment of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USATransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Corresponding author at: Transplant Research Center, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115, USA.Background: Nanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by enhancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in lymph nodes or formed de novo in peripheral tissues during inflammatory responses. They express peripheral node addressin (PNAd), which is recognized by the monoclonal antibody MECA79. Methods: Here, we demonstrated that HEVs form de novo in human pancreatic ductal adenocarcinoma (PDAC). We engineered MECA79 coated nanoparticles (MECA79-NPs) that recognize these ectopic HEVs in PDAC. Findings: The trafficking of MECA79-NPs following intravenous delivery to human PDAC implanted in a humanized mouse model was more robust than non-conjugated NPs. Treatment with MECA79-Taxol-NPs augmented the delivery of Paclitaxel (Taxol) to the tumor site and significantly reduced the tumor size. This effect was associated with a higher apoptosis rate of PDAC cells and reduced vascularization within the tumor. Interpretation: Targeting the HEVs of PDAC using MECA79-NPs could lay the ground for the localized delivery of a wide variety of drugs including chemotherapeutic agents. Fund: National Institutes of Health (NIH) grants: T32-EB016652 (B·B.), NIH Cancer Core Grant CA034196 (L.D.S.), National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (R.A.). Keywords: Pancreatic ductal adenocarcinoma, High endothelial venules, Peripheral node addressin, MECA79 coated nanoparticles, Taxolhttp://www.sciencedirect.com/science/article/pii/S2352396418305346 |
| spellingShingle | Baharak Bahmani Mayuko Uehara Farideh Ordikhani Xiaofei Li Liwei Jiang Naima Banouni Takaharu Ichimura Vivek Kasinath Siawosh K. Eskandari Nasim Annabi Jonathan S. Bromberg Leonard D. Shultz Dale L. Greiner Reza Abdi Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context EBioMedicine |
| title | Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context |
| title_full | Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context |
| title_fullStr | Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context |
| title_full_unstemmed | Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context |
| title_short | Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted deliveryResearch in context |
| title_sort | ectopic high endothelial venules in pancreatic ductal adenocarcinoma a unique site for targeted deliveryresearch in context |
| url | http://www.sciencedirect.com/science/article/pii/S2352396418305346 |
| work_keys_str_mv | AT baharakbahmani ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT mayukouehara ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT faridehordikhani ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT xiaofeili ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT liweijiang ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT naimabanouni ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT takaharuichimura ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT vivekkasinath ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT siawoshkeskandari ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT nasimannabi ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT jonathansbromberg ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT leonarddshultz ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT dalelgreiner ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext AT rezaabdi ectopichighendothelialvenulesinpancreaticductaladenocarcinomaauniquesitefortargeteddeliveryresearchincontext |